Alnylam Pharmaceuticals Inc. (ALNY) anticipates delivering non-GAAP operating income profitability in 2025.
Alnylam announced full year 2025 combined net product revenue guidance for ONPATTRO, AMVUTTRA (PN & CM), GIVLAARI and OXLUMO of $2.050 billion to $2.250 billion, representing combined full year growth compared to 2024 of 31% at the mid-point of the guidance range.
Preliminary global net product revenues for ONPATTRO and AMVUTTRA for the fourth quarter were approximately $56 million and $287 million, respectively.
Preliminary global net product revenues for GIVLAARI and OXLUMO for the fourth quarter were approximately $65 million and $44 million, respectively.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.